NZM.F NOVOZYMES A/S SPONS.ADR 1
- Market cap
- EUR 27.7B
- P/E
- 40.8x
- P/B
- 2.49x
- ROE
- 6.6%
- Dividend yield
- 1.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NZM.F undervalued?
Graham numberNZM.F trades 112.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NOVOZYMES A/S SPONS.ADR 1 fundamental analysis
No fundamental analysis for NOVOZYMES A/S SPONS.ADR 1 yet.
NOVOZYMES A/S SPONS.ADR 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NOVOZYMES A/S SPONS.ADR 1
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricult…
Full company profileNOVOZYMES A/S SPONS.ADR 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NOVOZYMES A/S SPONS.ADR 1 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.01B | 2.36B | 2.40B | 3.83B | 4.16B | 4.50B |
| Gross Profit | 1.16B | 1.29B | 1.30B | 1.81B | 2.24B | 2.54B |
| Operating Income | 522M | 594M | 611M | 659M | 883M | 1.09B |
| EBITDA | - | 821M | 734M | 1.04B | 1.39B | 1.09B |
| Net Income | 423M | 493M | 406M | 306M | 584M | 745M |
| EPS | 1.53 | 1.78 | 1.46 | 0.66 | 1.25 | 1.60 |
| Balance Sheet | ||||||
| Total Assets | 3.33B | 3.76B | 3.81B | 15.2B | 16.3B | 16.8B |
| Total Liabilities | 1.69B | 1.85B | 1.88B | 4.02B | 5.49B | 5.61B |
| Shareholders' Equity | 1.59B | 1.86B | 1.88B | 11.2B | 10.9B | 11.2B |
| Cash & Short-term Investments | 129M | 140M | 150M | 280M | 275M | 455M |
| Cash Flow | ||||||
| Operating Cash Flow | 546M | 538M | 557M | 1.02B | 1.22B | 1.20B |
| Capital Expenditure | 167M | 388M | 276M | 360M | 471M | 461M |
| Free Cash Flow | 379M | 150M | 281M | 660M | 751M | 737M |
| Ratios | ||||||
| ROE | 26.6% | 26.6% | 21.6% | 2.7% | 5.4% | 6.6% |
| ROA | 12.7% | 13.1% | 10.7% | 2.0% | 3.6% | 4.4% |
| Net Profit Margin | 21.0% | 20.9% | 16.9% | 8.0% | 14.0% | 16.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NOVOZYMES A/S SPONS.ADR 1 dividends
- Dividend yield
- 1.45%
- Forward dividend
- 0.87 EUR
- Payout ratio
- 69.0%
- Ex-dividend date
- Aug 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 403M | 0.86 | 69.0% |
| 2024 | EUR 250M | 0.54 | 81.7% |
| 2023 | EUR 383M | 1.38 | 94.4% |
| 2022 | EUR 205M | 0.74 | 41.5% |
| 2021 | DKK 197M | 0.71 | 46.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NOVOZYMES A/S SPONS.ADR 1
- Insiders 0.00%
- Institutions 4.59%
- Public & others 95.41%
- Shares outstanding 412M
- Free float 348M
NOVOZYMES A/S SPONS.ADR 1 company profile
- Company name
- NOVOZYMES A/S SPONS.ADR 1
- Ticker
- NZM.F
- Exchange
- Frankfurt Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 10,933
- Fiscal year end
- December
- Address
- Biologiens Vej 2, Lyngby, Denmark, 2800
- Phone
- 45 44 46 00 00
- Website
- novonesis.com
About NOVOZYMES A/S SPONS.ADR 1
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.
NOVOZYMES A/S SPONS.ADR 1 management
10- Ms. Ester BaigetPresident & CEO · born 1971
- Mr. Rainer LehmannExecutive VP & CFO · born 1975
- Mr. Anders LundChief Operating Officer · born 1973
- Mr. Claus Crone FuglsangChief Scientific Officer · born 1968
- Mr. Tobias Cornelius BjorklundHead of Investor Relations
- Mr. Morten Enggaard RasmussenExecutive Vice President of People & Stakeholder Relations · born 1976
- Mr. Tue MicheelsenPresident of Novonesis North America & Head of Global Consumer Health
- Ms. Tina Sejersgaard FanoExecutive Vice President of Planetary Health Biosolutions · born 1969
- Mr. Henrik Joerck NielsenEVP of Human Health Biosolutions and Strategy & Integration · born 1978
- Mr. Andrew TaylorExecutive Vice President of Food & Beverage Biosolutions